Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans

The current Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo is the second largest Ebola outbreak worldwide, with over 6,000 confirmed cases and a 48% fatality rate. There is currently no approved BDBV vaccine.